Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML Journal Article
| Authors: | Shaffer, B. C.; Le Luduec, J. B.; Park, S.; Devlin, S.; Archer, A.; Davis, E.; Cooper, C.; Nhaissi, M.; Suri, B.; Wells, D.; Tamari, R.; Papadopoulos, E.; Jakubowski, A. A.; Giralt, S.; Hsu, K. C. |
| Article Title: | Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML |
| Abstract: | Donor KIR and recipient HLA combinations that minimize inhibition and favor activation of the NK repertoire are associated with improved outcomes after allogeneic hematopoietic cell transplantation (HCT) in patients with myeloid neoplasia. We prospectively evaluated a weighted donor ranking algorithm designed to prioritize HLA-compatible unrelated donors (URDs) with weak inhibitory KIR3DL1/HLA-Bw4 interaction, followed by donors with nontolerized activating KIR2DS1, and finally those with KIR centromeric B haplotype. During donor evaluation, we performed KIR genotyping and ranked 2079 URDs for 527 subjects with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Among all patients, 394 (75%) had at least 1 KIR-advantageous donor, and 263 (50%) underwent HCT. In patients with AML, KIR3DL1 weak inhibition provided protection from relapse. Compared with KIR3DL1-Weak Inhibiting donors, KIR3DL1-Noninteracting donors were associated with increased risk of relapse (HR, 2.97; 95% CI, 1.33-6.64; P = .008) and inferior event-free survival (EFS; HR, 2.14; 95% CI, 1.16-3.95; P = .015). KIR3DL1-Strong Inhibiting donors were associated with HR, 1.65 (95% CI, 0.66-4.08; P = .25) for AML relapse and HR, 1.6 (95% CI, 0.81-3.17; P = .1) for EFS when compared with the use of KIR3DL1-weak inhibiting donors. Donor KIR2DS1/HLA-C1 status and centromeric KIR haplotype-B content were not associated with decreased risk of AML relapse. There was no benefit to KIR-based donor selection in patients with MDS. This study demonstrates that donor KIR typing is feasible, and prioritization of donors with certain KIR3DL1 genotypes may confer a protection from relapse after HCT in patients with AML. © 2021 by The American Society of Hematology. |
| Journal Title: | Blood Advances |
| Volume: | 5 |
| Issue: | 7 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-04-13 |
| Start Page: | 2003 |
| End Page: | 2011 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2020002701 |
| PUBMED: | 33843984 |
| PROVIDER: | scopus |
| PMCID: | PMC8045509 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work